Stryker (NYSE:SYK) Stock Gets Price Target Reduction from BTIG Research

Key Points

• BTIG Research lowered Stryker’s price target from $358 to $316 while maintaining a “buy” rating, implying approximately 14% upside from the prior close.
• Analyst sentiment remains positive overall: Stryker has a “Moderate Buy” consensus rating and an average price target of $369, despite several recent target reductions.
• Stryker reported quarterly EPS of $3.69, exceeding estimates, while revenue rose 9.4% year over year to $6.59 billion. The stock opened at $277.27, near its one-year low, and insiders have sold roughly $118.2 million in shares over the past 90 days.

Stryker (NYSE:SYK - Get Free Report) had its target price cut by stock analysts at BTIG Research from $358.00 to $316.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has a "buy" rating on the medical technology company's stock. BTIG Research's target price points to a potential upside of 13.97% from the stock's previous close.

A number of other equities research analysts also recently commented on SYK. Citigroup cut their price objective on Stryker from $399.00 to $360.00 and set a "buy" rating for the company in a research report on Thursday, September 10th. Royal Bank Of Canada dropped their target price on Stryker from $435.00 to $420.00 and set an "outperform" rating on the stock in a report on Friday, July 31st. Evercore set a $350.00 target price on Stryker in a research report on Monday, July 6th. Raymond James Financial set a $370.00 target price on Stryker in a report on Friday, July 31st. Finally, Barclays upgraded shares of Stryker to a "strong-buy" rating in a report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $369.00.

Stryker Stock Performance

Shares of Stryker stock opened at $277.27 on Monday. The firm has a market cap of $106.35 billion, a PE ratio of 28.73, a price-to-earnings-growth ratio of 1.75 and a beta of 0.78. The firm's 50-day simple moving average is $304.41 and its 200-day simple moving average is $314.21. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker has a 1 year low of $267.00 and a 1 year high of $392.55.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The firm's revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts forecast that Stryker will post 14.96 earnings per share for the current fiscal year.

Insider Activity

In other Stryker news, Director Ronda Stryker sold 50,000 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the sale, the director owned 2,251,375 shares of the company's stock, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Debra King sold 826 shares of the firm's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 351,267 shares of company stock valued at $118,197,701 in the last ninety days. 4.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SYK. State Street Corp lifted its stake in shares of Stryker by 1.2% during the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company's stock valued at $4,903,772,000 after buying an additional 183,400 shares in the last quarter. Wellington Management Group LLP grew its stake in Stryker by 0.6% in the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company's stock valued at $2,571,357,000 after buying an additional 45,478 shares in the last quarter. Bank of America Corp DE bought a new stake in Stryker during the 2nd quarter valued at $1,404,284,000. Royal Bank of Canada lifted its position in shares of Stryker by 6.5% during the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company's stock worth $1,075,552,000 after acquiring an additional 199,863 shares in the last quarter. Finally, Auto Owners Insurance Co lifted its position in shares of Stryker by 35,047.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company's stock worth $1,024,444,000 after acquiring an additional 2,906,448 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

About Stryker

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used in hospitals, surgical centers and other healthcare settings. Founded in 1941 by Dr. Homer Stryker in Kalamazoo, Michigan, the company has grown from an orthopedic device business into a diversified provider of medical technologies.

Stryker's product portfolio includes orthopedic implants and instruments, surgical equipment, neurovascular devices, spine products, patient-handling and emergency-care equipment, operating-room systems, and digital and robotic technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.